Global Expansion ROIS operates with FDA, EMA, ANVISA, PMDA and other major approvals and has recently expanded into the US with the Arizona plant acquisition, signaling a strong international growth trajectory and potential for cross-border CDMO collaborations.

Vaccine and Biologics Focus Strong expertise in aseptic fill-finish for vaccines and biologics (including mAb, mRNA, and oligonucleotides) creates opportunities to partner on advanced biologics programs, multipart vaccine projects, and lyophilized product WFI dossiers.

Full Scope Manufacturing End-to-end capabilities from scale-up to packaging, serialization and testing across multiple dosage forms position ROIS as a one-stop CDMO for clients seeking streamlined development-to-commercial production.

Capacity and Scale With 12 injectable filling lines and high-capacity finishing lines, ROIS can accommodate large or multiple parallel programs, appealing to companies needing scalable manufacturing for vaccines, biologics and injectables.

Strategic Partnerships Recent leadership appointment and acquisition activity indicate a proactive market expansion strategy, offering opportunities for collaboration in global commercial development, manufacturing partnerships, and strategic alliances.